regulatory is the most under-discussed thing on this board
regulatory is the most under-discussed thing on this board. Change my mind, genuinely — I have no stake in being right about this.
The three questions, kept separate, because this board runs them together constantly.
Identity: is this the sequence I ordered? Answered by mass spectrometry against a theoretical mass. Quantity: how much peptide is in the vial? Answered by net peptide content, not by area percent. Stability: what happens to it in solution over time? Answered by a stability statement with conditions attached, and almost never asked for.
A certificate that answers one of the three is common. One that answers all three is rare and worth choosing a supplier over. Nothing here is approved for human use in any case, so all three are questions about material rather than about anything else.
Bought small, tested identity first, and only then thought about anything else. That order felt right.
Why identity, not purity, is the test to buy here.
This is a short peptide with a published sequence. Synthesis is not difficult, which means the market is wide and the analytical question shifts. A high area-percent figure tells you the sample is homogeneous; it does not tell you the homogeneous material is the sequence you ordered.
Mass spectrometry, with the theoretical mass alongside the measured one, converts a purity claim into an identity claim. It costs a little more and it answers the question that actually matters. Ask for it, and ask suppliers whether they can provide it before you order — the answers are informative in themselves.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
The evidence base, described honestly, which almost no summary of it does.
The published literature is overwhelmingly preclinical and largely in rodent models. The individual papers are generally more modest in their claims than the summaries that circulate. Human clinical trial evidence for the claims most often repeated in these threads is very limited.
That is not an argument that nothing is happening in the preclinical work — some of it is genuinely interesting. It is an argument that the distance between "this happened in a rodent model" and "this will happen in a person" is large, uncertain, and crossed silently in nearly every confident post on this board, including some of mine from two years ago.
Left up. It distinguishes rodent work from human work, which is the standard on this board.
[removed by moderator]
That is a purity figure, not an identity confirmation. Two different tests and only one answers the question asked.
Correcting myself: I said the regulatory position had not changed and in that jurisdiction it has.
Yes. Nothing here is approved for human use and that should be the first line of every thread, not the last.
Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.
the human evidence is thin and the rodent evidence is not
identity testing matters more here than purity does
Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.
Reconstituted or powder, and how long has it been in solution?
Reconstituted or powder, and how long has it been in solution?
This is the point that should be at the top of every thread here. Identity first.
stability in solution is the practical question nobody asks
ask for the mass spectrum, not just the purity number
read the actual papers, they are more modest than the summaries
identity, quantity, stability — three separate questions
Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.
Sent a vial to Janoshik: 98.2% against a claimed 98.0%, with the mass confirming the sequence. Both halves mattered to me.
Ask for the theoretical mass alongside the measured one. It is a one-line addition to a certificate and it converts a purity claim into an identity claim.
Left up.
Adding the standing caveat — research material is not approved for human use, wherever you are.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
regulatory status varies by jurisdiction and it has moved recently
The published literature is overwhelmingly preclinical, largely in rodent models.
Agreed — and the preclinical to clinical gap is where nearly all the overclaiming happens.
Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.
Research-use-only material is not approved for human use.
search_before_post is right that a pure something-else is still something else.
- 1Left up. It distinguishes rodent work from human work, which is the standard…19 comments in this branch · started by u/bpc_sceptic